A PARP inhibitor, rucaparib, improves cardiac dysfunction in ADP-ribose-acceptor hydrolase 3 (Arh3) deficiency
Sachiko Yamashita, Xiangning Bu, Hiroko Ishiwata-Endo, Jiro Kato, Danielle Springer, Audrey C. Noguchi, Morteza Peiravi, Chengyu Liu, Fan Zhang, Zu‐Xi Yu, Randy Clevenger, Karen J. Keeran, Hong San, Martin J. Lizak, Joel Moss
This study shows that ARH3 deficiency causes cardiac dysfunction and that rucaparib, a PARP inhibitor, improves cardiac contractility and reduces infarct size in ARH3-deficient mice.
bioRxiv · Feb 7, 2023 · PreprintMolecular Biology